This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our studies aim at developing vaccine strategies that will prevent the establishment of HIV-infection. Vaccination strategies that only elicit cellular antiviral responses are not capable of sterilizing immunity, but can reduce the plasma viral load during the chronic phase of infection; prevent the rapid elimination of CD4+ T lymphocytes; and delay the development of disease. Vaccination methodologies that principally elicit neutralizing antibodies also offer protection (and in certain cases sterilizing immunity), but only against the homologous virus. This is due to the inability of currently used envelope immunogens to elicit cross-reactive neutralizing antibodies. The proposed studies are based on our observation that the partial elimination of the V2 loop from the SF162 envelope increases the exposure of conserved neutralization epitopes. Macaques immunized with this modified envelope, termed SF162deltaV2, but not with the unmodified SF162 envelope, generate antibodies that neutralize several heterologous primary HIV-1 isolates. We propose that the antibodies elicited by the SF162deltaV2 envelope immunogen will offer protection from heterologous viral challenge, while those elicited by the unmodified SF162 envelope immunogen will offer protection only from the homologous viral challenge. To test this hypothesis macaques will first be immunized with DNA vectors expressing the SIVmac239 Gag and Pol and either the SF162 or SF162deltaV2 envelope proteins, to elicit cellular responses against multiple antigens and subsequently immunized with the corresponding purified envelope protein to increase the titer of neutralizing antibodies. The animals will then be challenged with the homologous SHIVSF162P4 or the heterologous SHIV89.6P viruses.
Showing the most recent 10 out of 320 publications
